Spero Therapeutics: The Multi-Asset Pipeline Could Outpace The Tebipenem HBr Deal With GSKSeeking Alpha • 07/05/23
Spero Therapeutics Appoints Sath Shukla as President & Chief Executive OfficerGlobeNewsWire • 06/14/23
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/11/23
Spero Therapeutics Announces First Quarter 2023 Operating Results and Provides a Business UpdateGlobeNewsWire • 05/11/23
Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023GlobeNewsWire • 05/04/23
Spero Therapeutics: Massive Partnership Deal Still Not Properly Valued By The MarketSeeking Alpha • 04/21/23
Spero Therapeutics to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious DiseasesGlobeNewsWire • 04/14/23
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Beat EstimatesZacks Investment Research • 03/30/23
Spero Therapeutics Announces Fourth Quarter and Full Year 2022 Operating Results and Provides Business UpdateGlobeNewsWire • 03/30/23
Spero Therapeutics Reschedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call to March 30, 2023GlobeNewsWire • 03/13/23
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on Monday, March 13, 2023GlobeNewsWire • 03/06/23
Down -12.5% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a TurnaroundZacks Investment Research • 02/23/23
Spero Therapeutics, Inc. (SPRO) Loses -9.78% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 02/22/23
Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx ConferenceGlobeNewsWire • 11/22/22
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/14/22
Spero Therapeutics Announces Third Quarter 2022 Operating Results and Provides Business UpdateGlobeNewsWire • 11/14/22
Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBrGlobeNewsWire • 11/08/22
Spero Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on Monday, November 14, 2022GlobeNewsWire • 11/07/22
Spero Therapeutics, Inc. (SPRO) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 11/02/22